HAART slows progression to anal cancer in HIV-infected MSM

AIDS

Volumn 29, Issue 3, 2015, Pages 305-311

  Duncan, Katrina C ^a   Chan, Keith J ^b   Chiu, Connie G ^c   Montaner, Julio S G ^a   Coldman, Andy J ^d   Cescon, Angela ^b   Au Yeung, Christopher G ^b   Wiseman, Sam M ^c   Hogg, Robert S ^e   Press, Natasha M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^c ST PAUL S HOSPITAL   (Canada)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e SIMON FRASER UNIVERSITY   (Canada)

Author keywords

Anal cancer; Anal intraepithelial neoplasia; HAART; HIV; MSM

Indexed keywords

ADULT; ANUS CANCER; ARTICLE; CD4 LYMPHOCYTE COUNT; DISEASE COURSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; VIRUS LOAD; ANUS NEOPLASMS; COHORT ANALYSIS; COMPLICATION; DISEASE PREDISPOSITION; HIV INFECTIONS; IMMUNOLOGY; MALE HOMOSEXUALITY; MIDDLE AGED; TIME;

ANTIRETROVIRUS AGENT;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANUS NEOPLASMS; COHORT STUDIES; DISEASE SUSCEPTIBILITY; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84927597310     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000537     Document Type: Article

References (21)

1. D'Souza G, Wiley DJ, Li X, Chmiel JS, Margolick JB, Cranston RD, et al. Incidence and epidemiology of anal cancer in the multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 2008; 48:491-499
2. Piketty C, Selinger-Leneman H, Grabar S, Duvivier C, Bonmarchand M, Abramowitz L, et al. Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS 2008; 22:1203-1211
3. Guiguet M, Boué F, Cadranel J, Lang JM, Rosenthal E, Costagliola D, et al. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol 2009; 10:1152-1159
4. Crum-Cianflone NF, Hullsiek KH, Marconi VC, Ganesan A, Weintrob A, Barthel RV, et al. Anal cancers among HIV-infected persons: HAART is not slowing rising incidence. AIDS 2010; 24:535-543
5. Silverberg MJ, Lau B, Justice AC, Engels E, Gill MJ, Goedert JJ, et al. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis 2012; 54:1026-1034
6. Montaner JSG, Lima VD, Harrigan PR, Lourenco L, Yip B, Nosyk B, et al. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the 'HIV Treatment as Prevention' experience in a Canadian setting. PLoS One 2014; 9:e87872
7. Palefsky JM, Holly EA, Efirdc JT, Da Costa M, Jay N, Berry JM, et al. Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men. AIDS 2005; 19:1407-1414
8. Piketty C, Darragh TM, Heard I, Da Costa M, Bruneval P, Kazatchkine MD, et al. High prevalence of anal squamous intraepithelial lesions in HIV-positive men despite the use of highly active antiretroviral therapy. Sex Transm Dis 2004; 31:96-99
9. De Pokomandy A, Rouleau D, Ghattas G, Trottier H, Vezina S, Cote P, et al. HAART and progression to high-grade anal intraepithelial neoplasia in men who have sex with men and are infected with HIV. Clin Infect Dis 2011; 52:1174-1181
10. Palefsky JM. Anal cancer prevention in HIV-positive men and women. Curr Opin Oncol 2009; 21:433-438
11. Van Leeuwen MT, Vajdic CM, Middleton MG, McDonald AM, Law M, Kaldor JM, et al. Continuing declines in some but not all HIV-associated cancers in Australia after widespread use of antiretroviral therapy. AIDS 2009; 23:2183-2190
12. Reekie J, Kosa C, Engsig F, Monforte Ad, Wiercinska-Drapalo A, Domingo P, et al. Relationship between current level of immunodeficiency and nonacquired immunodeficiency syndrome-defining malignancies. Cancer 2010; 116:5306-5315
13. Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, et al. Incidence of types of cancer among HIVinfected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008; 148:728-736
14. Palefsky JM, Holly EA, Ralston ML, Da Costa M, Bonner H, Jay N, et al. Effect of highly active antiretroviral therapy on the natural history of anal squamous intraepithelial lesions and anal human papillomavirus infection. J Acquir Immune Defic Syndr 2001; 28:422-428
15. Piketty C, Cochand-Priollet B, Lanoy E, Si-Mohamed A, Trabelsi S, Tubiana R, et al. Lack of regression of anal squamous intraepithelial lesions despite immune restoration under cART. AIDS 2013; 27:401-406
16. Palefsky JM. Antiretroviral therapy and anal cancer: the good, the bad, and the unknown. Sex Transm Dis 2012; 39:501-503
17. Fagan SP, Bellows CF 3rd, Albo D, Rodriquez-Barradas M, Feanny M, Awad SS, et al. Length of human immunodeficiency virus disease and not immune status is a risk factor for development of anal carcinoma. Am J Surg 2005; 190:732-735
18. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services. pp. 1-167. http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/aa-recommendations.pdf. [Accessed 10 September 2012]
19. Palefsky JM, Giuliano AR, Goldstone S, Moreira ED, Aranda C, Jessen H, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011; 365:1576-1585
20. Simard EP, Watson M, Saraiya M, Clarke CA, Palefsky JM, Jemal A. Trends in the occurrence of high-grade anal intraepithelial neoplasia in San Francisco: 2000-2009. Cancer 2013; 119:3539-3545
21. Low-Beer S, Yip B, O'shaughnessy MV, Hogg RS, Montaner JS. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr 2000; 23:360-361.